For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novartis Suspected of Drafting Conference Presentation Materials on “Sign” Trial
January 31, 2014
- Novartis Global Net Profit Falls 1%, Japan Sales Drop 15.8%
January 31, 2014
- Maruho to Acquire Distribution Rights for Atopic Dermatitis Drug Protopic from Astellas
January 31, 2014
- Sawai, Nichi-Iko Boosting Annual Production Capacity to 10 Billion Tablets Each in Anticipation of Future Market Growth
January 31, 2014
- Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
- Sosei Transfers NorLevo MA Rights to ASKA
January 30, 2014
- Mochida Eyes 10 Billion Yen Generic Biz, Valsartan Combination Drug to Debut in 2014: Pres.
January 29, 2014
- Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
- Lurasidone Receives CHMP Positive Opinion: DSP, Takeda
January 29, 2014
- Kenko.com Sues Government over Restriction of Online OTC Drug Sales
January 28, 2014
- Asano Named as New Asahi Kasei President
January 28, 2014
- Zydus to Withdraw from Japan, Discontinuing Shipments by March-End Due to Policy Change of Parent Company
January 28, 2014
- Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
- BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
January 27, 2014
- Sanwa Kagaku, Dong-A ST of South Korea Sign License Deal for Nesp Biosimilar in Japan
January 27, 2014
- Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
- Antidepressant Brintellix Launched in US: Takeda, Lundbeck
January 24, 2014
- Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
- Novartis Pharma Involvement Suspected in Drafting of Sign Trial Protocol
January 23, 2014
- Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…